What if you could inject a significantly smaller dose of toxic chemotherapy directly into a malignant tumor site and stop its growth? The potential benefits range from greatly reduced drug side effects, to a complete remission of the disease, to an inoculation against future cancer growth. For Intensity Therapeutics, these results have already been shown in mice, and the company is now conducting human clinical trials at some of the leading cancer hospitals in the country.
Intensity Therapeutics, Inc. is a biotechnology company whose mission is to greatly extend the lives of patients with solid tumor cancers with its pioneering new immunotherapy approach to treat cancer called in situ vaccination.
The company has made significant progress since our last investment, including receiving approval from the FDA to test its product in humans and receiving numerous issued patents. The safety data in humans thus far has been good, and the company has received approval to test its product in deep body tumors. In the next twelve months, the company expects to add additional subjects and hospital sites for its trials, thereby allowing it to also test various dose frequencies and volume.